any patients with hypertension have concomitant hypercholesterolemia [1] [2] [3] and it has been reported that reductions in cholesterol levels correlate with lower diastolic blood pressure (DBP). 4 Further, experimental and clinical studies have demonstrated a strong correlation between high plasma cholesterol levels and impaired endothelium-dependent vascular relaxation. [5] [6] [7] These findings suggest that hypercholesterolemia may contribute to increased vascular reactivity and thereby contribute to systemic hypertension.
Clinical Parameters
BP (SBP and DBP) was measured with patients in the supine position after at least 30 min of rest. Two consecutive measurements were obtained using a mercury sphygmomanometer, and the average of the measurements was calculated. Fasting blood samples were drawn by venipuncture between 08.00 and 10.00 h for the measurement of plasma LDL-C, high-density lipoprotein-cholesterol (HDL-C), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), creatine kinase (CK), serum glucose (FBS), serum creatinine (Cr), blood urea nitrogen (BUN), and uric acid (UA). The laboratory and clinical data, including body mass index (BMI) and heart rate (HR), were compared among the various experimental groups before and after pravastatin treatment. We examined the correlations among the percent changes of SBP, DBP, and LDL-C to evaluate the relationship between BP change and LDL-C change by pravastatin treatment. We also compared the percent changes of BP between the different antihypertensive treatments to evaluate the difference in BP-lowering effect of pravastatin with concomitant antihypertensive drugs.
Statistical Analysis
Data are expressed as mean ± SD. The differences between groups were compared using Student's t-test, and comparisons between continuous and categorical variables were performed using the chi-square test. Intragroup data were analyzed using paired t-tests. Correlative factors of pravastatin treatment were tested using multiple logistic regression analysis. A p-value <0.05 was considered to represent statistical significance.
Results
The baseline characteristics of the HT and NT groups are summarized in Table 1 . There were no significant differences in age, sex ratio, BMI, DBP, HR, lipids, or other laboratory parameters between the 2 groups. SBP was significantly reduced in the HT group after 3 months of treatment with pravastatin (134±16 to 130±13 mmHg, p<0.005), but DBP remained unchanged (79±11 to 77±8 mmHg, p=0.33) ( Table 2) , and treatment had no effect on SBP (124±10 to 123±9 mmHg, p=0.52) or DBP (76±9 to 75±8 mmHg, p= 0.61) in the NT group (Table 2) . Pravastatin treatment sig- nificantly reduced plasma LDL-C (HT group 178±27 to 132±17 mg/dl, p<0.0001; NT group 169±27 to 125± 21 mmHg, p<0.0001) and TG (HT group 150±58 to 130± 39 mg/dl, p<0.05; NT group 154±62 to 124±32 mmHg, p<0.005) in both groups but did not affect plasma HDL-C (HT group 54±14 to 52±12 mg/dl, p=0.48; NT group 57±18 to 54±16 mmHg, p=0.44) ( Table 2 ) or other parameters (BMI, HR, AST, ALT, LDH, CK, FBS, Na, K, Cl, BUN, Cr, and UA). Baseline data from the controlled and uncontrolled BP groups are summarized in Table 3 . There were no significant differences in age, sex ratio, BMI, DBP, lipid data, or the distribution of antihypertensive drugs. In the uncontrolled BP group, SBP (148±7 to 138±12 mmHg, p<0.005) and DBP (82±13 to 77±9 mmHg, p<0.005) was significantly reduced after 3 months of treatment with pravastatin (Table 4) . Further, pravastatin treatment significantly reduced plasma LDL-C levels in both groups (uncontrolled BP group 176±29 to 130±20 mg/dl, p<0.0001; controlled BP group 179±25 to 134±14 mmHg, p<0.0001) but did not affect HDL-C (uncontrolled BP group 56±13 to 55± 14 mg/dl, p=0.81; controlled BP group 53±15 to 51± 11 mg/dl, p=0.60) or TG (uncontrolled BP group 142±57 to 132±49 mg/dl, p=0.55; controlled BP group 156±60 to 128±30 mg/dl, p=0.08) or other parameters (BMI, HR, AST, ALT, LDH, CK, FBS, Na, K, Cl, BUN, Cr, and UA; Table 4 ).
There was a significant correlation between the percentage changes in SBP and DBP in the HT group (R=0.68, p<0.0001) and uncontrolled BP group (R=0.78, p<0.0001). Changes in the systolic and diastolic blood pressure (BP) and low-density lipoprotein-cholesterol (LDL-C) level in the uncontrolled BP group according to pravastatin treatment. Before, before pravastatin treatment; 1M, 1 month after pravastatin treatment; 2M, 2 months after pravastatin treatment; 3M, 3 months after pravastatin treatment. **p<0.005, ***p<0.0001.
However, there was no significant correlation between the percentage changes in plasma LDL-C and SBP or DBP in either the HT group (R=-0.07, p=0.65; R=0.04, p=0.80, respectively) (Fig 1) or uncontrolled BP group (R=-0.014, p=0.95; R=0.11, p=0.64, respectively) (Fig 2) . There was no significant change in BP after 1 or 2 months of pravastatin treatment, although LDL-C significantly decreased in the uncontrolled BP group (Fig 3) . Multiple logistic regression analysis of the parameters of LDL-C and SBP, with or without pravastatin and hypertriglyceridemia (≥150 mg/dl) revealed that LDL-C (p< 0.0001) and SBP (p=0.036) were significantly and independently correlated with pravastatin treatment (Table 5) .
Percent reduction of SBP was significantly larger in uncontrolled BP patients taking an angiotensin-converting enzyme (ACE) inhibitor than in those without it, although there was no significant difference in the percent reduction of LDL-C (Table 6 ).
Discussion
The present study has demonstrated that pravastatin treatment resulted in improved BP control and lipid profiles in hypertensive and hypercholesterolemic patients who were already receiving antihypertensive drugs. Furthermore, pravastatin significantly improved SBP control in patients with uncontrolled BP, but not in patients with controlled BP.
Sposito et al 14 and Borghi et al 15 previously reported that statins can augment BP control in hypertensive and hypercholesterolemic patients on antihypertensive therapy. Although Borghi et al 16 also demonstrated that statins produced a significant decrease in SBP and DBP in patients with SBP ≥140 mmHg, other studies have reported that statins had no effect on BP in normotensive patients [18] [19] [20] [21] [22] or those with well-controlled hypertension. [23] [24] [25] [26] In combination with the present observations, the evidence suggests that the effect of statins on BP is likely to be restricted to patients with concomitant hypercholesterolemia and uncontrolled hypertension, in whom modulation of peripheral vascular tone and vascular resistance is significantly impaired.
The present study also demonstrated that there was no correlation between the change in BP and the change in LDL-C in response to pravastatin. By contrast, Borghi et al 15 reported a weak linear relationship between the percentage change in DBP and the percentage change in plasma total cholesterol, but no relationship between the percentage change in plasma total cholesterol and the change in SBP, in patients undergoing concomitant treatment with statins and antihypertensive drugs. Thus, they concluded that the additional BP reduction observed in patients treated with statins was only partially attributed to a lipid-lowering effect. Furthermore, other cholesterollowering agents, such as fibrates 27 and cholestyramine, 28 had no effect on BP in hypertensive patients, despite producing reductions in cholesterol level that were equivalent to those produced by statins. The present study showed that SBP, as well as LDL-C, was significantly and independently correlated with pravastatin treatment. These results suggest that pravastatin may modulate BP through some mechanism other than lipid lowering.
It is likely that the mechanism by which statins affect BP is related to the modulation of peripheral vascular tone and vascular resistance in patients with hypertension and hypercholesterolemia. Although we did not examine endothelial function or pulse wave velocity in the present study, Glorioso et al 12 reported that pravastatin blunted the pressor response to the cold pressor test and reduced the levels of circulating endothelin-1 with BP reduction in hypertensive and hypercholesterolemic patients. Endothelial dysfunction often accompanies hypercholesterolemia and hypertension, and several studies have demonstrated that a statin-induced reduction in cholesterol results in improved endothelium-dependent vasodilation, [29] [30] [31] possibly by increasing nitric oxide (NO) synthase activity and expression [32] [33] [34] and by inhibiting endothelin-1 production. 35 These findings suggest that improvement of endotheliumdependent vasodilation by statins may lower BP in hypertensive patients with hypercholesterolemia. However, Glorioso et al demonstrated that BP was significantly lowered after 8-12 weeks of statin treatment, 12 but our data also showed no significant change in BP after 1 or 2 months of pravastatin treatment in uncontrolled BP patients. Thus, direct vasodilation induced by NO may not be the major mechanism of the BP-lowering effect of pravastatin. Because the NO system also modulates the remodeling of the vascular bed, 36 vascular remodeling may be related to its effect. Furthermore, Ferrier et al demonstrated that systemic arterial compliance was higher after statin treatment com- pared with placebo. 13 Thus, reduction of arterial stiffness also may be a mechanism of the BP-lowering effect of statins. Other potential mechanisms are inhibition of calcium influx 37 and/or reduction in plasma levels of aldosterone. 38 The BP-lowering effect of pravastatin may vary with the type of concomitant antihypertensive treatment in patients with hypertension and hypercholesterolemia. Previous studies show a greater decrease in BP with the combination of statins and ACE inhibitors or calcium-channel blockers compared with other classes of antihypertensive drugs. [14] [15] [16] In the present study, the decrease in SBP with ACE inhibitors was greater than that without it in patients with uncontrolled BP and hypercholesterolemic who were taking pravastatin. A recent study demonstrated that in hypercholesterolemic patients statin combined with ACE inhibitor showed significantly more improvement of endotheliumdependent vasodilation than ACE inhibitor alone. 39 Because ACE inhibitors reduce BP by potentiating endotheliummediated vasodilatation and by reducing peripheral vascular tone, 40 interactions between the effect of the statins and the vasorelaxant effect of the ACE inhibitor may underlie the mechanism by which statins modulate BP. Previous studies have also demonstrated that LDL-C induces upregulation of the expression of the AT1 receptor in vascular smooth muscle cells and increased activity of angiotensin II, 41, 42 and that statins reverse the elevated BP response to angiotensin II infusion and downregulate AT1 receptor density. 43 Statins also inhibits angiotensin II-mediated vascular remodeling via an anti-inflammatory effect that is independent of their cholesterol-lowering activity. 44 The effects of statins on the AT1 receptor may enhance the BPlowering effect of ACE inhibitors.
In terms of the differential effect of the various statins, Sposito et al reported that the BP reduction by lovastatin or pravastatin was similar, 14 whereas Borghi et al reported that the decrease in DBP was greater in response to pravastatin than to simvastatin. 15 Further studies investigating the differential effects of statins are needed.
Recent clinical studies in Japan, similar to those performed in Western countries, [45] [46] [47] [48] [49] indicate a reduction in coronary events 50, 51 and stroke risk in patients with vascular disease. 52 Furthermore, statins promote regression of left ventricular mass. 53 Because BP is one of the most important factors in cardiac remodeling and cardiovascular diseases, the additional reduction in BP in patients treated with pravastatin may also contribute to the reduced risk of cardiovascular disease and cardiac hypertrophy.
Study Limitations
This study was retrospective, not a randomized doubleblind, placebo-controlled cross-over trial. Thus, a placebolike hypotensive effect of pravastatin cannot be completely excluded.
Conclusion
This study demonstrated that the addition of pravastatin to existing antihypertensive therapy, especially ACE inhibitors, decreased BP in Japanese patients with hypertension and hypercholesterolemia.
